Optimal care of lupus nephritis patients

Abstract

Optimal care of lupus nephritis patients should include the treatment of proteinuria and hypertension, other measures to delay the progression of chronic kidney disease, the vigorous management of cardiovascular risk factors and finally, the treatment of advanced chronic kidney disease and its consequences. These topics are briefly reviewed in the present paper, with particular emphasis on the recent progresses in antiproteinuric treatment.

Keywords

cardiovascular chronic kidney disease hypertension lupus nephritis proteinuria systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Bjornadal L , Yin L , Granath F , Klareskog L , Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95 . Journal of Rheumatology 2004; 31: 713-719 .

Remuzzi G , Bertani T. Pathophysiology of progressive nephropathies . New England Journal of Medicine 1998; 339: 1448-1456 .

Taal MW , Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists . Kidney International 2000; 57: 1803-1817 .

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD. The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy . New England Journal of Medicine 1993; 329: 1456-1462 .

Maschio G , Alberti D , Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency . New England Journal of Medicine 1996; 334: 939-945 .

Ruggenenti P , Perna A , Mosconi L et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy . Lancet 1997; 349: 1857-1863 .

Ruggenenti P , Perna A , Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial . Lancet 1998; 352: 1252-1256 .

Ruggenenti P , Perna A , Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria . Lancet 1999; 354: 359-364 .

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . New England Journal of Medicine 2001; 345: 851-860 .

10.

Brenner BM , Cooper ME , de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . New England Journal of Medicine 2001; 345: 861-869 .

11.

Jafar TH , Schmid CH , Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - a meta-analysis of patient-level data . Annals of Internal Medicine 2001; 135: 73-87 .

12.

Campbell R , Sangalli F , Perticucci E et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies . Kidney International 2003; 63: 1094-1103 .

13.

Jacobsen PK , Andersen S , Rossing K , Jensen BR , Parving HH. Dual blockade of the renin angiotensin system versus maximal recommended dose of ACE-inhibition in Type 1 patients with diabetic nephropathy . Diabetologia 2003; 46: A339-A339 .

14.

Nakao N , Yoshimura A , Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial . Lancet 2003; 361: 1230-1230 .

15.

Ruggenenti P , Perna A , Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria . Kidney International 2003; 63: 2254-2261 .

16.

Buter H , Hemmelder MH , Navis G , de Jong PE , de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide . Nephrology Dialysis Transplantation 1998; 13: 1682-1685 .

17.

Bakris GL , Weir MR.

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - is this a cause for concern?

Archives of Internal Medicine 2000; 160: 685-693 .

18.

Ruggenenti P , Mise N , Pisoni R et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies . Circulation 2003; 107: 586-592 .

19.

Houssiau FA , Vasconcelos C , D’Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial . Arthritis Rheum; in press.

20.

Bessant R , Hingorani A , Patel L et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus . Rheumatology 2004; 43: 924-929 .

21.

Mancia G , Rosei EA , Cifkova R et al. 2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension . Journal of Hypertension 2003; 21: 1011-1053 .

22.

Chobanian AV , Bakris GL , Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Hypertension 2003; 42: 1206-1252 .

23.

Levey AS. Nondiabetic kidney disease . New England Journal of Medicine 2002; 347: 1505-1511 .

24.

Bakris GL , Weir MR , Secic M , Campbell B , Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression . Kidney International 2004; 65: 1991-2002 .

25.

Locatelli F , Del Vecchio L.

How long can dialysis be postponed by low protein diet and ACE inhibitors?

Nephrology Dialysis Transplantation 1999; 14: 1360-1364 .

26.

Wilmer WA , Rovin BH , Hebert CJ et al. Management of glomerular proteinuria: a commentary . Journal of the American Society of Nephrology 2003; 14: 3217-3232 .

27.

Klahr S , Levey AS , Beck GJ et al. The effects of dietary-protein restriction and blood-pressure control on the progression of chronic renal-disease . New England Journal of Medicine 1994; 330: 877-884 .

28.

Roman MJ , Shanker B , Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . New England Journal of Medicine 2003; 349: 2399-2406 .

29.

Asanuma Y , Oeser A , Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus . New England Journal of Medicine 2003; 349: 2407-2415 .

30.

Smith CR. Lipid-lowering therapy - new and established agents reduce risk of cardiovascular events . Postgraduate Medicine 2004; 115: 29-36 .

31.

McCarey DW , McInnes LB , Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial . Lancet 2004; 363: 2015-2021 .

32.

Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis . New England Journal of Medicine 2003; 349: 2379-2380 .

33.

Devuyst O , Goffin E , Pirson Y , Destrihou CV. Creatinine rise after fibrate therapy in renal graft recipients . Lancet 1993; 341: 840-840 .

34.

Martinez-Berriotxoa A , Ruiz-Irastorza G , Arberas MVE , Gutierrez MR , Errasti CA. Plasma homocysteine levels in systemic lupus erythematosus . Medicina Clinica 2003; 120: 681-685 .

35.

De Vriese AS , Verbeke F , Schrijvers BF , Lameire NH.

Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?

Kidney International 2002; 61: 1199-1209 .

36.

Lange H , Suryapranata H , De Luca G et al. Folate therapy and in-stent restenosis after coronary stenting . New England Journal of Medicine 2004; 350: 2673-2681 .

37.

Ohlenschlaeger T , Garred P , Madsen HO , Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus . New England Journal of Medicine 2004; 351: 260-267 .

38.

Ifudu O , Dawood M , Homel P , Friedman EA. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist . American Journal of Kidney Diseases 1996; 28: 841-845 .

39.

Jungers P , Zingraff J , Albouze G et al. Late referral to maintenance dialysis - detrimental consequences . Nephrology Dialysis Transplantation 1993; 8: 1089-1093 .

40.

Kinchen KS , Sadler J , Fink N et al. The timing of specialist evaluation in chronic kidney disease and mortality . Annals of Internal Medicine 2002; 137: 479-486 .

41.

Locatelli F , Aljama PA , Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure . Nephrology Dialysis Transplantation 2004; 19: 1-47 .

42.

Eknoyan G , Levin A , Levin NW. Bone metabolism and disease in chronic kidney disease . Am J Kidney Dis 2003; 42(suppl. 3): S1-S201 .